Fluorine in PDB 3omq: Fragment-Based Design of Novel Estrogen Receptor Ligands
Protein crystallography data
The structure of Fragment-Based Design of Novel Estrogen Receptor Ligands, PDB code: 3omq
was solved by
S.Moecklinghoff,
W.A.Van Otterlo,
R.Rose,
S.Fuchs,
M.Dominguez Seoane,
H.Waldmann,
C.Ottmann,
L.Brunsveld,
with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:
Resolution Low / High (Å)
|
19.55 /
1.97
|
Space group
|
P 31
|
Cell size a, b, c (Å), α, β, γ (°)
|
70.590,
70.590,
110.090,
90.00,
90.00,
120.00
|
R / Rfree (%)
|
20.5 /
26
|
Fluorine Binding Sites:
The binding sites of Fluorine atom in the Fragment-Based Design of Novel Estrogen Receptor Ligands
(pdb code 3omq). This binding sites where shown within
5.0 Angstroms radius around Fluorine atom.
In total 6 binding sites of Fluorine where determined in the
Fragment-Based Design of Novel Estrogen Receptor Ligands, PDB code: 3omq:
Jump to Fluorine binding site number:
1;
2;
3;
4;
5;
6;
Fluorine binding site 1 out
of 6 in 3omq
Go back to
Fluorine Binding Sites List in 3omq
Fluorine binding site 1 out
of 6 in the Fragment-Based Design of Novel Estrogen Receptor Ligands
Mono view
Stereo pair view
|
A full contact list of Fluorine with other atoms in the F binding
site number 1 of Fragment-Based Design of Novel Estrogen Receptor Ligands within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
A:F1
b:26.9
occ:1.00
|
FAK
|
A:W231
|
0.0
|
26.9
|
1.0
|
CAJ
|
A:W231
|
1.4
|
21.7
|
1.0
|
FAM
|
A:W231
|
2.2
|
23.0
|
1.0
|
FAL
|
A:W231
|
2.3
|
23.4
|
1.0
|
SAR
|
A:W231
|
2.4
|
19.9
|
1.0
|
OAQ
|
A:W231
|
2.6
|
15.3
|
1.0
|
OAP
|
A:W231
|
2.9
|
19.8
|
1.0
|
ND1
|
A:HIS475
|
3.7
|
27.2
|
1.0
|
CD1
|
A:ILE373
|
3.7
|
25.2
|
1.0
|
CG1
|
A:ILE373
|
3.7
|
19.6
|
1.0
|
NAN
|
A:W231
|
3.9
|
19.7
|
1.0
|
CG
|
A:HIS475
|
4.0
|
21.8
|
1.0
|
CB
|
A:HIS475
|
4.0
|
20.5
|
1.0
|
CD1
|
A:ILE376
|
4.1
|
14.9
|
1.0
|
O
|
A:GLY472
|
4.2
|
15.8
|
1.0
|
CE
|
A:MET295
|
4.3
|
13.0
|
1.0
|
CE1
|
A:HIS475
|
4.4
|
24.4
|
1.0
|
CA
|
A:GLY472
|
4.5
|
15.5
|
1.0
|
CAI
|
A:W231
|
4.5
|
18.1
|
1.0
|
CAF
|
A:W231
|
4.6
|
14.8
|
1.0
|
C
|
A:GLY472
|
4.8
|
16.5
|
1.0
|
CD2
|
A:HIS475
|
4.9
|
21.4
|
1.0
|
SD
|
A:MET295
|
4.9
|
17.8
|
1.0
|
CD1
|
A:LEU476
|
4.9
|
25.8
|
1.0
|
N
|
A:LEU476
|
4.9
|
19.9
|
1.0
|
|
Fluorine binding site 2 out
of 6 in 3omq
Go back to
Fluorine Binding Sites List in 3omq
Fluorine binding site 2 out
of 6 in the Fragment-Based Design of Novel Estrogen Receptor Ligands
Mono view
Stereo pair view
|
A full contact list of Fluorine with other atoms in the F binding
site number 2 of Fragment-Based Design of Novel Estrogen Receptor Ligands within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
A:F1
b:23.4
occ:1.00
|
FAL
|
A:W231
|
0.0
|
23.4
|
1.0
|
CAJ
|
A:W231
|
1.3
|
21.7
|
1.0
|
FAM
|
A:W231
|
2.2
|
23.0
|
1.0
|
FAK
|
A:W231
|
2.3
|
26.9
|
1.0
|
SAR
|
A:W231
|
2.5
|
19.9
|
1.0
|
NAN
|
A:W231
|
3.0
|
19.7
|
1.0
|
CAF
|
A:W231
|
3.0
|
14.8
|
1.0
|
OAP
|
A:W231
|
3.0
|
19.8
|
1.0
|
CD1
|
A:ILE373
|
3.3
|
25.2
|
1.0
|
CD1
|
A:LEU298
|
3.5
|
12.9
|
1.0
|
OAQ
|
A:W231
|
3.6
|
15.3
|
1.0
|
CAI
|
A:W231
|
3.8
|
18.1
|
1.0
|
CE
|
A:MET295
|
3.9
|
13.0
|
1.0
|
CB
|
A:LEU298
|
4.2
|
10.9
|
1.0
|
CG1
|
A:ILE373
|
4.2
|
19.6
|
1.0
|
SD
|
A:MET295
|
4.3
|
17.8
|
1.0
|
CG
|
A:LEU298
|
4.5
|
11.2
|
1.0
|
CAB
|
A:W231
|
4.6
|
14.3
|
1.0
|
|
Fluorine binding site 3 out
of 6 in 3omq
Go back to
Fluorine Binding Sites List in 3omq
Fluorine binding site 3 out
of 6 in the Fragment-Based Design of Novel Estrogen Receptor Ligands
Mono view
Stereo pair view
|
A full contact list of Fluorine with other atoms in the F binding
site number 3 of Fragment-Based Design of Novel Estrogen Receptor Ligands within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
A:F1
b:23.0
occ:1.00
|
FAM
|
A:W231
|
0.0
|
23.0
|
1.0
|
CAJ
|
A:W231
|
1.3
|
21.7
|
1.0
|
FAL
|
A:W231
|
2.2
|
23.4
|
1.0
|
FAK
|
A:W231
|
2.2
|
26.9
|
1.0
|
SAR
|
A:W231
|
2.4
|
19.9
|
1.0
|
OAQ
|
A:W231
|
2.7
|
15.3
|
1.0
|
CAI
|
A:W231
|
3.0
|
18.1
|
1.0
|
NAN
|
A:W231
|
3.0
|
19.7
|
1.0
|
CD1
|
A:ILE373
|
3.1
|
25.2
|
1.0
|
CG1
|
A:ILE373
|
3.7
|
19.6
|
1.0
|
OAP
|
A:W231
|
3.8
|
19.8
|
1.0
|
CAF
|
A:W231
|
3.8
|
14.8
|
1.0
|
CG2
|
A:ILE376
|
3.9
|
16.2
|
1.0
|
CE1
|
A:PHE377
|
4.3
|
11.0
|
1.0
|
CD1
|
A:ILE376
|
4.3
|
14.9
|
1.0
|
CB
|
A:ILE376
|
4.5
|
14.8
|
1.0
|
CAD
|
A:W231
|
4.6
|
18.0
|
1.0
|
CD1
|
A:PHE377
|
4.8
|
12.2
|
1.0
|
CD1
|
A:LEU298
|
4.8
|
12.9
|
1.0
|
CB
|
A:ILE373
|
4.9
|
18.3
|
1.0
|
CG2
|
A:ILE373
|
5.0
|
17.5
|
1.0
|
|
Fluorine binding site 4 out
of 6 in 3omq
Go back to
Fluorine Binding Sites List in 3omq
Fluorine binding site 4 out
of 6 in the Fragment-Based Design of Novel Estrogen Receptor Ligands
Mono view
Stereo pair view
|
A full contact list of Fluorine with other atoms in the F binding
site number 4 of Fragment-Based Design of Novel Estrogen Receptor Ligands within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
B:F1
b:23.8
occ:1.00
|
FAK
|
B:W231
|
0.0
|
23.8
|
1.0
|
CAJ
|
B:W231
|
1.3
|
20.9
|
1.0
|
FAM
|
B:W231
|
2.2
|
22.9
|
1.0
|
FAL
|
B:W231
|
2.3
|
21.6
|
1.0
|
SAR
|
B:W231
|
2.4
|
20.8
|
1.0
|
OAQ
|
B:W231
|
2.7
|
16.5
|
1.0
|
OAP
|
B:W231
|
2.9
|
18.2
|
1.0
|
CD1
|
B:ILE373
|
3.6
|
24.9
|
1.0
|
CG1
|
B:ILE373
|
3.6
|
20.2
|
1.0
|
NAN
|
B:W231
|
3.9
|
20.2
|
1.0
|
ND1
|
B:HIS475
|
3.9
|
26.5
|
1.0
|
CG
|
B:HIS475
|
4.0
|
22.4
|
1.0
|
CB
|
B:HIS475
|
4.1
|
20.4
|
1.0
|
CD1
|
B:ILE376
|
4.1
|
15.3
|
1.0
|
O
|
B:GLY472
|
4.3
|
14.8
|
1.0
|
CE
|
B:MET295
|
4.3
|
13.5
|
1.0
|
CA
|
B:GLY472
|
4.4
|
15.1
|
1.0
|
CAI
|
B:W231
|
4.5
|
18.0
|
1.0
|
CE1
|
B:HIS475
|
4.5
|
25.2
|
1.0
|
CAF
|
B:W231
|
4.6
|
14.4
|
1.0
|
CD2
|
B:HIS475
|
4.7
|
22.8
|
1.0
|
C
|
B:GLY472
|
4.8
|
16.0
|
1.0
|
CG2
|
B:ILE376
|
4.9
|
16.6
|
1.0
|
|
Fluorine binding site 5 out
of 6 in 3omq
Go back to
Fluorine Binding Sites List in 3omq
Fluorine binding site 5 out
of 6 in the Fragment-Based Design of Novel Estrogen Receptor Ligands
Mono view
Stereo pair view
|
A full contact list of Fluorine with other atoms in the F binding
site number 5 of Fragment-Based Design of Novel Estrogen Receptor Ligands within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
B:F1
b:21.6
occ:1.00
|
FAL
|
B:W231
|
0.0
|
21.6
|
1.0
|
CAJ
|
B:W231
|
1.3
|
20.9
|
1.0
|
FAM
|
B:W231
|
2.1
|
22.9
|
1.0
|
FAK
|
B:W231
|
2.3
|
23.8
|
1.0
|
SAR
|
B:W231
|
2.5
|
20.8
|
1.0
|
CAF
|
B:W231
|
3.1
|
14.4
|
1.0
|
OAP
|
B:W231
|
3.1
|
18.2
|
1.0
|
NAN
|
B:W231
|
3.1
|
20.2
|
1.0
|
CD1
|
B:ILE373
|
3.3
|
24.9
|
1.0
|
CD1
|
B:LEU298
|
3.5
|
11.9
|
1.0
|
OAQ
|
B:W231
|
3.7
|
16.5
|
1.0
|
CE
|
B:MET295
|
3.8
|
13.5
|
1.0
|
CAI
|
B:W231
|
3.9
|
18.0
|
1.0
|
CB
|
B:LEU298
|
4.1
|
10.7
|
1.0
|
CG1
|
B:ILE373
|
4.2
|
20.2
|
1.0
|
SD
|
B:MET295
|
4.3
|
16.7
|
1.0
|
CG
|
B:LEU298
|
4.4
|
10.1
|
1.0
|
CAB
|
B:W231
|
4.6
|
14.6
|
1.0
|
|
Fluorine binding site 6 out
of 6 in 3omq
Go back to
Fluorine Binding Sites List in 3omq
Fluorine binding site 6 out
of 6 in the Fragment-Based Design of Novel Estrogen Receptor Ligands
Mono view
Stereo pair view
|
A full contact list of Fluorine with other atoms in the F binding
site number 6 of Fragment-Based Design of Novel Estrogen Receptor Ligands within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
B:F1
b:22.9
occ:1.00
|
FAM
|
B:W231
|
0.0
|
22.9
|
1.0
|
CAJ
|
B:W231
|
1.3
|
20.9
|
1.0
|
FAL
|
B:W231
|
2.1
|
21.6
|
1.0
|
FAK
|
B:W231
|
2.2
|
23.8
|
1.0
|
SAR
|
B:W231
|
2.5
|
20.8
|
1.0
|
OAQ
|
B:W231
|
2.8
|
16.5
|
1.0
|
NAN
|
B:W231
|
3.1
|
20.2
|
1.0
|
CAI
|
B:W231
|
3.1
|
18.0
|
1.0
|
CD1
|
B:ILE373
|
3.1
|
24.9
|
1.0
|
CG1
|
B:ILE373
|
3.6
|
20.2
|
1.0
|
OAP
|
B:W231
|
3.8
|
18.2
|
1.0
|
CAF
|
B:W231
|
3.8
|
14.4
|
1.0
|
CG2
|
B:ILE376
|
3.9
|
16.6
|
1.0
|
CE1
|
B:PHE377
|
4.1
|
10.7
|
1.0
|
CD1
|
B:ILE376
|
4.5
|
15.3
|
1.0
|
CB
|
B:ILE376
|
4.5
|
14.1
|
1.0
|
CD1
|
B:PHE377
|
4.6
|
12.1
|
1.0
|
CAD
|
B:W231
|
4.6
|
16.9
|
1.0
|
CD1
|
B:LEU298
|
4.6
|
11.9
|
1.0
|
CB
|
B:ILE373
|
4.9
|
17.6
|
1.0
|
CG2
|
B:ILE373
|
5.0
|
16.6
|
1.0
|
|
Reference:
W.A.Van Otterlo,
R.Rose,
S.Fuchs,
T.J.Zimmermann,
M.Dominguez Seoane,
H.Waldmann,
C.Ottmann,
L.Brunsveld.
Design and Evaluation of Fragment-Like Estrogen Receptor Tetrahydroisoquinoline Ligands From A Scaffold-Detection Approach. J.Med.Chem. V. 54 2005 2011.
ISSN: ISSN 0022-2623
PubMed: 21381753
DOI: 10.1021/JM1011116
Page generated: Wed Jul 31 21:19:18 2024
|